Fig 2: Anti-Hsp70 antibody levels in the serum of patients before, and at indicated time-points after radiation therapy.Time course of anti-Hsp70 antibodies in the serum of patients with SCCHN tumors before and after therapy. Blood was collected and anti-Hsp70 antibodies were determined by anti-Hsp70 antibody ELISA. Standard box plots are shown with boundaries indicating the 25th and the 75th percentile. The line inside boxes indicates the median and the whiskers indicate the 10th and 90th percentile, respectively. All outliers are shown in the graph. (healthy n = 4, patients before therapy n = 16, patients after therapy at least 6 weeks after radiation therapy n = 6).

Fig 3: Correlation of tumor volume with Hsp70 protein and anti-Hsp70 antibody serum levels in patients with SCCHN. Tumor volumes were determined by manually contouring the gross tumor volume (GTV) of patients based on contrast enhanced computer tomography scans before radiation therapy. The assessed tumor volumes in ml were associated with the sHsp70 serum (A, n = 13) and anti-Hsp70 antibody (B, n = 10) levels as determined by ELISA. Linear regression was determined by SigmaPlot statistical software.

Fig 4: Effect of sample handling methods, storage conditions, and storage time on HSP70 concentration (ng/mL) in skim milk before and after storage. Vertical lines represent the SEM. Bars with different letters indicate significant differences (P < 0.05) based on Sidak-adjusted pairwise comparisons within each combination of sample handling method, storage condition, and storage time. The dashed line represents expression of HSP70 at d 1 without storage effect.

Fig 5: Experimental design of storage conditions to detect HSP70 in raw bovine milk. SBS = skimmed before storage; SAS = skimmed after storage; T1 = room temperature (∼22°C); T2 = refrigerated (4°C); T3 = frozen (−20°C); T4 = adding bronopol preservative and refrigerated (4°C).